CA
NZ
UK
AU
IND
US
Cencora, Inc. raised its full-year adjusted EPS guidance to between $17.75 and $17.95, reflecting strong performance within its specialty pharmaceutical platform during Q3 2026. This raises investor confidence in Cencora’s long-term outlook, particularly as it strengthens its position in the healthcare market.
Doximity's share price surged 50% in response to excitement over its medical AI initiatives, elevating the market capitalization to approximately $3.7 billion. This rally signals investor optimism but raises concerns about potential cannibalization of the company's core networking business.Key HighlightsPrice $28.00 (+35.5% today) · …
Saccaro will take a key role in steering the company's global finance operations and enhancing its capital allocation strategy. This appointment comes as Zoetis aims to strengthen its operational execution, particularly regarding manufacturing and supply chain management. Given the company’s year-to-date share decline of …
This strong performance, which included first half 2026 revenue growth of 60%, has led the medical technology company to increase its full year 2026 net revenue guidance to a range of $67 million to $69 million. The revised outlook represents approximately 42% to 46% …
SpyGlass Pharma posted a net loss of $19.9 million, or $0.59 per share, for the quarter ended June 30, a sharp increase from the $8.7 million loss a year earlier. Earnings per share came in at $‑0.69 versus a consensus estimate of $‑0.51, underscoring …
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported a net loss of $21.2 million for the second quarter ending June 30, 2026, marking a significant recovery from the previous year's loss of $52.4 million. The earnings per share (EPS) came in at $-0.31, beating a …
This performance aligns with the company’s strategy to strengthen its market position for its TriNav system, a device integral to their innovative oncology treatments. The stable revenue stream indicates resilience amid ongoing economic pressures, bolstering confidence among investors looking for growth in the healthcare …
The quarterly results exceeded expectations, with earnings per share of $-0.47, outperforming the consensus estimate of $-0.56. This financial positioning signals a cautious but positive trajectory as Voyager focuses on its pipeline for neurological diseases, particularly Alzheimer's treatment. Maintaining investor confidence amid a volatile …
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) affirmed its strategy for expedited regulatory review of its investigational WEE1 inhibitor, azenosertib, following productive discussions with the U.S. regulatory agency. The company disclosed its financial performance for the second quarter concluded June 30, 2026, along with updates on …
This strong performance, which included first half 2026 revenue growth of 60%, has led the medical technology company to increase its full year 2026 net revenue guidance to a range of $67 million to $69 million. The revised outlook represents approximately 42% to 46% …
Please wait processing your request...